<DOC>
	<DOCNO>NCT01804101</DOCNO>
	<brief_summary>This randomize clinical trial study liposomal cytarabine-daunorubicin CPX-351 treating patient untreated myelodysplastic syndrome acute myeloid leukemia . Drugs use chemotherapy , liposomal cytarabine-daunorubicin CPX-351 , work different way stop growth cancer cell , either kill cell , stop dividing , stop spreading .</brief_summary>
	<brief_title>Liposomal Cytarabine-Daunorubicin CPX-351 Treating Patients With Untreated Myelodysplastic Syndrome Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Estimate whether 32 units/m^2 64 units/m^2 dose level CPX-351 ( liposomal cytarabine-daunorubicin CPX-351 ) likely improve treatment-related mortality ( TRM ) rate keep complete remission ( CR ) rate constant patient untreated high-risk myelodysplastic syndrome ( MDS ) non-acute promyelocytic leukemia ( APL ) acute myeloid leukemia ( AML ) high risk TRM . SECONDARY OBJECTIVES : I . Describe CR/CR incomplete platelet count recovery ( CRp ) rate 4 cycle induction/re-induction therapy . II . Describe event-free survival , disease-free survival , overall survival patient achieve CR/CRp . III . Estimate frequency severity regimen-associated toxicity . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : INDUCTION/RE-INDUCTION : Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 intravenously ( IV ) 90 minute day 1 , 3 , 5 . Treatment repeat every 40 day 4 course absence disease progression unacceptable toxicity . Patients achieve CR CRp continue consolidation . CONSOLIDATION : Patients receive lower-dose liposomal cytarabine-daunorubicin CPX-351 IV 90 minute day 1 3 . Treatment repeat every 40 day 4 course absence disease progression unacceptable toxicity . ARM II : ( close accrual effective 4/21/14 ) INDUCTION/RE-INDUCTION : Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV 90 minute day 1 , 3 , 5 . Treatment repeat every 40 day 4 course absence disease progression unacceptable toxicity . Patients achieve CR CRp continue consolidation . CONSOLIDATION : Patients receive higher-dose liposomal cytarabine-daunorubicin CPX-351 IV 90 minute day 1 3 . Treatment repeat every 40 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Biphenotypic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Diagnosis untreated `` highrisk '' MDS ( &gt; = 10 % blast ) AML acute promyelocytic leukemia ( APL ) ( 15 ; 17 ) ( q22 ; q12 ) variant accord 2008 World Health Organization ( WHO ) classification ; patient biphenotypic AML eligible ; outside diagnostic material acceptable long peripheral blood and/or bone marrow slide review study institution cytogenetic/molecular information available Prior hydroxyurea AML permit discontinue prior start CPX351 treatment Azacitidine , decitabine , lenalidomide , growth factor permit lowrisk MDS ( &lt; 10 % blast ) ; treatment MDS discontinue prior start CPX351 treatment Treatmentrelated mortality ( TRM ) score &gt; = 13.1 calculate simplified model Bilirubin &lt; 2.0 mg/mL x upper limit normal ; requirement reflect excretion CPX351 liver Aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 4.0 x upper limit normal ; requirement reflect excretion CPX351 liver Left ventricular ejection fraction ( LVEF ) &gt; = 40 % , assess within 28 day prior registration , e.g . multi gated acquisition ( MUGA ) scan echocardiography , appropriate diagnostic modality Patients symptoms/signs hyperleukocytosis white blood cell ( WBC ) &gt; 100,000/uL treated leukapheresis prior enrollment Provide sign write informed consent Refractory/relapsing blast crisis chronic myelogenous leukemia ( CML ) Concomitant illness associate likely survival &lt; 1 year Active systemic fungal , bacterial , viral , infection , unless treatment antimicrobial controlled/stable , define afebrile hemodynamically stable 2448 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>